Previous research has indicated that NF-κB promotes EGFR-TKI’s resistance to NSCLC [86] and NF-κB inhibition could facilitate EGFR-TKI’s sensitivity [84]. Here, NFKB1 is linked to non-small cell lung carcinoma.